Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia

• Published in: Blood Vol. 128; no. 22; p. 4395
• Main Authors: Seymour, John F, Davids, Matthew S., Roberts, Andrew W., Hallek, Michael, Wierda, William G., Hillmen, Peter, Gerecitano, John F., Cerri, Elisa, Potluri, Jalaja, Kim, Su Young, Busman, Todd, Verdugo, Maria, Humerickhouse, Rod A., Best, Andrea, Desai, Monali, Stilgenbauer, Stephan
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 02.12.2016

▪ Background: Venetoclax (VEN) is a potent, highly selective, orally bioavailable small-molecular BCL2 inhibitor that is FDA-approved for patients (pts) with chronic lymphocytic leukemia (CLL) that harbors del(17p) and who have received ≥1 prior therapy. VEN monotherapy induces objective response in...